Reserach On The Treatment Of Hp Related Chronic Gastritis By Bifidobacterium-Lactobacillus-Enterococcus And Triple Therapy

Objective:Evaluating the cure rate of Bifidobacterium-Lactobacillus-Enterococcus (Bifico) and triple therapy for Hp related chronic gastritis.Methods:180 cases of patients who with a confirmative diagnosis of Hp related chronic gastric and have no history of Hp treatment. Randomly divided into four groups:triple therapy (group A), Bifico+triple therapy (group B), triple therapy+Bifico (group C), Bifico+triple therapy+ Bifico (group D), after six weeks treatment, Evaluating the Hp eradication rate, counting the remission rate of adverse events or symptoms and the incidence of adverse events or symptoms. Result:The Hp eradication rates of each groups is 59.1% in group A,67.5% in group B,69.4%in group C, and 82.9% in group D (p=0.121).All the three groups with Bifico demonstrated improved cure rate compare with the traditional triple regimen, and group D with the addition of Bifico pre-post triple regimen treatment shows the strongest effect.Conclusion:Bifico can bring beneficial effects to the triple regimen treatment of Hp in terms of eradication rate and adverse events control. Bifico+triple therapy+Bifico may be the best choice.